# OnCo record paper-topaz-1-nejm-evidence-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-topaz-1-nejm-evidence-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-topaz-1-nejm-evidence-2022" ;
  schema:name "TOPAZ-1: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer"@en ;
  schema:description "Adding durvalumab to gemcitabine-cisplatin lengthened survival in advanced bile duct and gallbladder cancer, the first improvement on chemotherapy alone in more than a decade, with about a quarter of patients alive at two years."@en ;
  schema:url <https://onco.cc/key-papers/paper-topaz-1-nejm-evidence-2022/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/EVIDoa2200015>, <https://pubmed.ncbi.nlm.nih.gov/38319896/> ;
  schema:sameAs <https://doi.org/10.1056/EVIDoa2200015> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Oh DY, Ruth He A, Qin S, et al." ;
  onco:cancers <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/> ;
  onco:drugs <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:trials <https://onco.cc/trials/topaz-1/> ;
  onco:journals <https://onco.cc/journals/nejm-evidence/> .